News

Onvansertib is a first-in-class, third generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor. Trovagene executive chairman Dr Thomas Adams said: “The European Commission’s decision to grant orphan

The study results, as well as the results of Sonoma’s previous HOCl acne studies (total of 127 patients), were presented by the principal investigator, Mark Steven Nestor, M.D.,

Under the terms of the agreement, Purdue will pay Assertio a total of $62 million in cash, with $30 million in cash paid on August 28, 2018 and

As part of the deal, Affimed will authorize its redirected optimized cell killing (ROCK) platform to discover and optimize innate immune cell engager-based immunotherapeutics of interest to Genentech.

Harbour BioMed is engaged in the discovery and development of therapeutics for oncology and immunological diseases. The financing round was led by GIC Private Limited, and participants included

The approved indications are for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory,

Xerava has been developed for the treatment of cIAI in patients 18 years of age and older. In clinical trials, Xerava has showed statistical non-inferiority to two widely

The company has secured approval from the Food and Drug Administration for drugs with strengths of 3 mg/0.02 mg/0.451 mg and 0.451 mg (EQ Beyaz). Lupin’s Drospirenone, Ethinyl

CogniCann is one of MXC’s medical cannabis pharmaceutical products with a THC:CBD ratio specifically formulated to treat key Dementia symptoms and enhance specific cognitive functions. The approval was